VENETOCLAX
Information current as at: 1 April 2024
Submission Details
- Brand name:
-
- Venclexta®
- Pharmaceutical company:
- AbbVie Pty Ltd
- Condition/indication:
(therapeutic use) -
- Acute myeloid leukaemia
- PBAC Submission type:
- Change to listing (Resubmission)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2021
- Related medicines:
Progress Details
-
Submission received for: - July 2021 PBAC meeting
-
Opportunity for consumer comment: - Open 21/03/2021 and close 26/05/2021 (see PBS Website)
-
PBAC meeting: - Held on 07/07/2021
-
Lodgement of required documentation: - 13/08/2021
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 27/08/2021
-
Status:
- Finalised
-
Government processes: - Commenced on 20/09/2021
-
Medicine listed on the PBS: - 01/12/2021 (see PBS schedule)
Case ID: a382
Page last updated: 04 April 2024